Table 1. Characteristics of patients with drug susceptible, multidrug-resistant and extensively drug-resistant tuberculosis.
| DS | MDR | XDR | MDR vs DS | XDR vs DS | |||
| N | 116 | 123 | 139 | OR | CI | OR | CI |
| Age, median (IQR) | 35 (29–43) | 34 (29–43) | 34 (29–42) | p = 0.75 | p = 1.00 | ||
| Female, n (%) | 49 (42) | 53 (43) | 78 (56) | 1.04 | (0.62–1.73) | 1.75 | (1.06–2.88)* |
| Extrapulmonary, n (%) | 26 (22) | 34 (28) | 41 (30) | 1.32 | (0.73–2.38) | 1.45 | (0.82–2.56) |
| Previous TB Treatment | |||||||
| Past year, n (%) | 18 (16) | 73 (59) | 82 (59) | 7.94 | (4.28–14.75)* | 7.83 | (4.27–14.35)* |
| Ever, n (%) | 31 (27) | 92 (75) | 96 (69) | 8.13 | (4.56–14.51)* | 6.12 | (3.54–10.57)* |
| Previous treatment status known, n (%) | 26 (84) | 70 (76) | 78 (81) | ||||
| Previous treatment status: cure, n (%) ϶ | 19 (73) | 17 (24) | 15 (19) | 0.82 | (0.40–1.67) | 0.62 | (0.30–1.28) |
| Previous treatment status: default, n (%) ϶ | 6 (23) | 10 (14) | 4 (5) | 1.62 | (0.57–4.62) | 0.54 | (0.15–1.97) |
| Previous treatment status: failure, n (%) ϶ | 1 (4) | 43 (61) | 59 (76) | 61.81 | (8.34–458.13)* | 84.81 | (11.51–624.80)* |
| Previous Hospitalization | |||||||
| Past year, n (%) | 13 (11) | 56 (46) | 73 (53) | 6.62 | (3.36–13.04)* | 8.76 | (4.50–17.06)* |
| Ever, n (%) | 23 (20) | 69 (56) | 83 (60) | 5.17 | (2.90–9.22)* | 5.99 | (3.39–10.58)* |
| Hospitalized >14 days, past year, n (%) | 4 (3) | 32 (26) | 43 (31) | 9.85 | (3.36–28.87)* | 12.5 | (4.34–36.21)* |
| Days Hospitalized, past year ° | |||||||
| median (range) | 11 (4–36) | 17 (6–109) | 18 (3–105) | 1.12 | (1.07–1.17)* | 1.14 | (1.08–1.19)* |
| Weight, median (IQR) (kg) | 52 (46–57) | 48 (45–58) | 50 (45–56) | p = 0.32 | p = 0.15* | ||
| Hemoglobin, median (IQR) (g/dL) | 9.4 (7.7–10.8) | 9.8 (7.9–11.5) | 9.0 (7.7–10.4) | p = 0.28 | p = 0.97 | ||
| Albumin, median (IQR) (g/dL) | 25.7 (20.8–31.5) | 28.0 (7.85–11.45) | 21.0 (18.7–25.7) | p = 0.56 | p = 0.26 | ||
| HIV tested, n (%) | 90 (78) | 92 (75) | 117 (85) | ||||
| HIV positive, n (% tested) | 78 (87) | 85 (92) | 115 (98) | 1.87 | (0.70–4.99) | 8.85 | (1.93–40.62)* |
| CD4 Count Available, n (%)† | 30 (38) | 43 (51) | 39 (34) | ||||
| Median (IQR)§ | 110.5 (41–223) | 87 (27–222) | 60 (26–164) | p = 0.56 | p = 0.09* | ||
| <200 cells/mm2 | 21 (70) | 31 (72) | 34 (87) | 1.11 | (0.40–3.09) | 2.91 | (0.86–9.88)* |
| ART Before TB Diagnosis, n (%)† | 3 (4) | 13 (15) | 25 (22) | 4.51 | (1.23–16.50)* | 6.94 | (2.02–23.90)* |
| Median duration among treated, days | 113 | 62 | 120 | p = 0.42 | p = 0.77 | ||
°Days hospitalized are considered among patients who were hospitalized.
†
CD4 cell count available and ART received before TB diagnosis were calculated among the fraction of patients known to have HIV.
§
CD4 cell count was included if it was drawn within 120 days of TB diagnosis.
*Indicates p-value of <0.2 (candidate for multivariable model).
϶Percents calculated from fraction of patients with known retreatment; referent group for ORs was all patients without this retreatment classification (e.g. referent for ‘retreatment without cure’ includes previously untreated patients and those wiith other retreatment class).